Business
Presentations of pre|CISION® Platform Candidates
Avacta Group PLC announced that it will present preclinical and translational data for its pre|CISION® platform candidates at the 2026 AACR Annual Meeting from April 17-22, 2026. Two presentations will detail AVA6103, a FAP-enabled peptide-drug conjugate delivering exatecan with sustained release and potent antitumor activity, and novel pre|CISION® compounds designed to deliver complementary dual payloads to the tumor microenvironment following FAP cleavage. These presentations highlight the company's progress in developing its tumor-activated oncology delivery platform. Disclaimer*
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n\n \n\nAvacta Announces Preclinical and Translational Presentations of pre|CISION® Platform Candidates at the 2026 AACR Annual Conference\n \n \nLONDON and PHILADELPHIA - March 17, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced it will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA.\n \nDetails of the two presentations:\n \nTitle: AVA6103 is a FAP-enabled pre|CISION® peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity\n \nAuthors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Michelle Morrow, Francis Wilson\n \nPoster number and Location: 5846, Section 17, Board 15\nSession: Tumor Microenvironment, Multi-specifics, and Immunomodulation\nSection: Experimental and Molecular Therapeutics\nTiming: Tuesday, 21 April 2026, 2:00-5:00pm PDT\n \n \n \nTitle: Characterization and translational development of novel pre|CISION® technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage\n \nAuthors: Victoria Juskaite, Tom Clough, Ellen Watts , Alexa Kennedy, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Greg Billenness, Douglas Sammon, Sophie Brown, Curtis Rink , Ruairidh Edwards, Vidicha Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David Jones\n \nPoster number and Location: 5656, Section 10, Board 26\nSession: Antibody-Drug Conjugates and Linker Engineering 4\nSection: Experimental and Molecular Therapeutics\nTiming: Tuesday 21 April 2026, 2:00-5:00pm PDT\n \n \n \n-Ends-\n \nFor further information from Avacta, please contact:\n \n\n\n\n\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\n\n\nhttps://avacta.com/\nvia Cohesion Bureau\n\n\n\n\n\n\n\n\n\n\n\n\n\nStrand Hanson Limited (Nominated Adviser)\nJames Harris / Chris Raggett / James Dance\n \n \n...